Plus Therapeutics Inc (PSTV)
Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer
Oncotelic Therapeutics, Inc. (OTLC)
Oncotelic Therapeutics Announces Publication of Landmark Study on TGFB2 Gene Methylation as a Positive Prognostic Marker in Pancreatic Cancer
Portage Biotech Inc. (PRTG)
Portage Biotech Inc. (PRTG)
Kymera Therapeutics Inc (KYMR)
Kymera Therapeutics Inc (KYMR)
Kymera Therapeutics Inc (KYMR)
Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update
The Joint Corp (JYNT)
The Joint Corp. Signs Binding Agreement to Sell 31 Corporate Clinics in Arizona and New Mexico and to Acquire Regional Developer Rights in the Northwest Region and Refranchises Five Corporate Clinics in the Kansas City Region, Tracking to Become Largest Pure Play Chiropractic Care Franchise System
Viking Therapeutics Inc. (VKTX)
Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735
Indaptus Therapeutics Inc. (INDP)
Indaptus Therapeutics Notification (INDP)
Amicus Therapeutics Inc (FOLD)
Amicus Therapeutics Announces Approval ofPombiliti® (cipaglucosidase alfa) +Opfolda® (miglustat) in Japan
Rewalk Robotics Ltd (LFWD)
Gilead Sciences Inc (GILD)
Gilead - Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
CalciMedica Inc (CALC)
CalciMedica Announces Publication in the American Journal of Nephrology Discussing Design and Rationale of Phase 2 KOURAGE Trial ofAuxora™ in AKI with Respiratory Failure
STAAR Surgical Company (STAA)
New Form 8-K - STAAR SURGICAL CO Filed: 2025-06-25 AccNo: 0000950170-25-089733 Size: 202 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits